These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 2665778)

  • 1. Alien antigens return to the fold.
    Parham P
    Immunol Today; 1989 Jun; 10(6):206-12. PubMed ID: 2665778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
    Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms.
    Gattoni-Celli S; Calorini L; Simile MM; Ferrone S
    Melanoma Res; 1993 Aug; 3(4):285-9. PubMed ID: 8219762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene transfer preferentially selects MHC class I positive tumour cells and enhances tumour immunogenicity.
    Hacker UT; Schildhauer I; Barroso MC; Kofler DM; Gerner FM; Mysliwietz J; Buening H; Hallek M; King SB
    Cancer Immunol Immunother; 2006 May; 55(5):547-57. PubMed ID: 16044254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of transplantation immunology with major histocompatibility complex knockout mice.
    Chitilian HV; Auchincloss H
    J Heart Lung Transplant; 1997 Feb; 16(2):153-9. PubMed ID: 9059926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA vaccines against HPV-16 E7-expressing tumour cells.
    De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A
    Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-class II antibodies, but not cytotoxic T-lymphocyte antigen 4-immunoglobulin hybrid molecules, prevent rejection of major histocompatibility complex class II-negative myeloma in T-cell receptor-transgenic mice.
    Dembic Z; Hofgaard PO; Omholt H; Bogen B
    Scand J Immunol; 2004; 60(1-2):143-52. PubMed ID: 15238083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
    Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
    Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism and evolution of HLA class I and II genes and molecules.
    Little AM; Parham P
    Rev Immunogenet; 1999; 1(1):105-23. PubMed ID: 11256568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major histocompatibility complex class II expression is required for posttransplant immunological but not hemopoietic reconstitution in mice.
    Huss R; Beckham C; Storb R; Deeg HJ
    Transplantation; 1994 Dec; 58(12):1366-71. PubMed ID: 7809930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines.
    Racioppi L; Carbone E; Grieco M; Del Vecchio L; Berlingieri MT; Fusco A; Boncinelli E; Zappacosta S; Fontana S
    Cancer Res; 1988 Jul; 48(13):3816-21. PubMed ID: 3378218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human MHC class I chain related (MIC) genes: their biological function and relevance to disease and transplantation.
    Collins RW
    Eur J Immunogenet; 2004 Jun; 31(3):105-14. PubMed ID: 15182323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological profiling of a panel of human ovarian cancer cell lines.
    Carr TM; Adair SJ; Fink MJ; Hogan KT
    Cancer Immunol Immunother; 2008 Jan; 57(1):31-42. PubMed ID: 17579858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulation of expression of histocompatibility antigens on the cell surface; molecular genetic basis.
    Petrányi GG
    Folia Biol (Praha); 1995; 41(3-4):163-77. PubMed ID: 7589712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cell-specific transcription of a murine histocompatibility class Ib Q5 gene.
    Noguchi K; Kuwada E; Goto S; Egawa K
    Anticancer Res; 2004; 24(5C):3379-86. PubMed ID: 15515435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological unresponsiveness induced by recipient cells transfected with donor MHC genes.
    Madsen JC; Superina RA; Wood KJ; Morris PJ
    Nature; 1988 Mar; 332(6160):161-4. PubMed ID: 3279318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.